Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study

被引:20
作者
Brockmann, Kathrin [1 ,2 ,3 ]
Schulte, Claudia [1 ,2 ,3 ]
Deuschle, Christian [1 ,2 ,3 ]
Hauser, Ann-Kathrin [1 ,2 ,3 ]
Heger, Tanja [1 ,2 ,3 ]
Gasser, Thomas [1 ,2 ,3 ]
Maetzler, Walter [1 ,2 ,3 ]
Berg, Daniela [1 ,2 ,3 ]
机构
[1] Univ Tubingen, Dept Neurodegenerat Dis, D-72076 Tubingen, Germany
[2] Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany
[3] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany
关键词
Parkinson; CSF; Tau; Abeta; LRRK2; GBA; MINI-MENTAL-STATE; PARKINSONS-DISEASE; CEREBROSPINAL-FLUID; COGNITIVE DECLINE; AMYLOID-BETA; GLUCOCEREBROSIDASE MUTATIONS; T-TAU; DEMENTIA; PROGRESSION; LEWY;
D O I
10.1016/j.parkreldis.2015.10.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Parkinson's disease (PD) patients show a large phenotypic variability probably reflecting inter-individual pathologic heterogeneity. Next to typical Lewy-body pathology, beta-amyloid (A beta) and tau pathology have been found at autopsy and several studies have reported altered CSF levels of A beta 1-42, total-Tau (t-Tau) and phosphorylated-Tau (p-Tau). Objectives: To evaluate whether CSF levels of neurodegenerative markers are influenced by genetics and whether specific subgroups of PD are more prone to a concomitant pathology possibly reflecting aspects of disease progression. Methods: In an explorative study we assessed CSF profiles of A beta 1-42, t-Tau, and p-Tau longitudinally in PD patients carrying LRRK2 (n = 5) or GBA mutations (n = 12), sporadic PD patients (n = 30) and healthy controls (n = 16). Results: Compared to healthy controls, all three PD cohorts showed lower levels of A beta 1-42. Moreover, sporadic PD and GBA-PD patients presented with lower levels of t-Tau and p-Tau whereas this phenomenon was not seen in LRRK2-PD patients. Regression analyses revealed an association between higher levels of Baseline p-Tau with more accelerated cognitive deterioration over time in LRRK2-PD and GBA-PD patients, but not in sporadic PD. Conclusion: PD patients present with disease-specific CSF profiles of A beta 1-42, t-Tau and p-Tau arguing in favor of an involvement of these proteins in PD pathogenesis in both sporadic and genetic forms. Moreover, we found first hints for differences in these CSF profiles between genetically determined PD cohorts but that CSF constellations which tend to predict aspects of disease progression such as cognitive decline seem similar across subgroups of PD. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1427 / 1434
页数:8
相关论文
共 36 条
[1]   The rate of cognitive decline in Parkinson disease [J].
Aarsland, D ;
Andersen, K ;
Larsen, JP ;
Perry, R ;
Wentzel-Larsen, T ;
Lolk, A ;
Kragh-Sorensen, P .
ARCHIVES OF NEUROLOGY, 2004, 61 (12) :1906-1911
[2]   Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers [J].
Aasly, J. O. ;
Shi, M. ;
Sossi, V. ;
Stewart, T. ;
Johansen, K. K. ;
Wszolek, Z. K. ;
Uitti, R. J. ;
Hasegawa, K. ;
Yokoyama, T. ;
Zabetian, C. P. ;
Kim, H. M. ;
Leverenz, J. B. ;
Ginghina, C. ;
Armaly, J. ;
Edwards, K. L. ;
Snapinn, K. W. ;
Stoessl, A. J. ;
Zhang, J. .
NEUROLOGY, 2012, 78 (01) :55-61
[3]   CSF Aβ42 predicts early-onset dementia in Parkinson disease [J].
Alves, Guido ;
Lange, Johannes ;
Blennow, Kaj ;
Zetterberg, Henrik ;
Andreasson, Ulf ;
Forland, Marthe G. ;
Tysnes, Ole-Bjorn ;
Larsen, Jan P. ;
Pedersen, Kenn F. .
NEUROLOGY, 2014, 82 (20) :1784-1790
[4]   CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study [J].
Alves, Guido ;
Bronnick, Kolbjorn ;
Aarsland, Dag ;
Blennow, Kaj ;
Zetterberg, Henrik ;
Ballard, Clive ;
Kurz, Martin Wilhelm ;
Andreasson, Ulf ;
Tysnes, Ole-Bjorn ;
Larsen, Jan Petter ;
Mulugeta, Ezra .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (10) :1080-1086
[5]   Cellular co-localization of phosphorylated tau- and NACP/α-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies [J].
Arima, K ;
Hirai, S ;
Sunohara, N ;
Aoto, K ;
Izumiyama, Y ;
Uéda, K ;
Ikeda, K ;
Kawai, M .
BRAIN RESEARCH, 1999, 843 (1-2) :53-61
[6]   GBA-associated PD presents with nonmotor characteristics [J].
Brockmann, K. ;
Srulijes, K. ;
Hauser, A. -K. ;
Schulte, C. ;
Csoti, I. ;
Gasser, T. ;
Berg, D. .
NEUROLOGY, 2011, 77 (03) :276-280
[7]   GBA-Associated Parkinson's Disease: Reduced Survival and More Rapid Progression in a Prospective Longitudinal Study [J].
Brockmann, Kathrin ;
Srulijes, Karin ;
Pflederer, Sylvia ;
Hauser, Ann-Kathrin ;
Schulte, Claudia ;
Maetzler, Walter ;
Gasser, Thomas ;
Berg, Daniela .
MOVEMENT DISORDERS, 2015, 30 (03) :407-411
[8]   Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers [J].
Brockmann, Kathrin ;
Groeger, Adriane ;
Di Santo, Adriana ;
Liepelt, Inga ;
Schulte, Claudia ;
Klose, Uwe ;
Maetzler, Walter ;
Hauser, Ann-Kathrin ;
Hilker, Ruediger ;
Gomez-Mancilla, Baltazar ;
Berg, Daniela ;
Gasser, Thomas .
MOVEMENT DISORDERS, 2011, 26 (13) :2335-2342
[9]  
Chiaravalloti A, 2014, EUR J NUCL MED MOL I, V41, P2137, DOI 10.1007/s00259-014-2841-4
[10]   Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? [J].
Compta, Yaroslau ;
Parkkinen, Laura ;
O'Sullivan, Sean S. ;
Vandrovcova, Jana ;
Holton, Janice L. ;
Collins, Catherine ;
Lashley, Tammaryn ;
Kallis, Constantinos ;
Williams, David R. ;
de Silva, Rohan ;
Lees, Andrew J. ;
Revesz, Tamas .
BRAIN, 2011, 134 :1493-1505